Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Dactolisib + Everolimus|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Dactolisib||NVP-BEZ235|BEZ235||ATR Inhibitor 10 mTOR Inhibitor 51 PI3K Inhibitor (Pan) 37||Dactolisib (BEZ235) inhibits PI3K kinase, mTOR kinase, and ATR, which may result in tumor cell apoptosis and growth inhibition of tumor cells (PMID: 18606717, PMID: 21552262, PMID: 32088816).|
|Everolimus||Afinitor||RAD001|Zortress||mTORC1 Inhibitor 8||Afinitor (everolimus) binds to FKBP-12 and allosterically inhibits mTOR, leading to decreased mTORC1 signaling and potentially resulting in decreased tumor cell growth (PMID: 17766661, PMID: 28400999). Afinitor (everolimus) is FDA approved for use in neuroendocrine tumors of pancreatic, lung or gastrointestinal tract origin, advanced renal cell carcinoma, in adult and pediatric patients aged 1 year and older with tuberous sclerosis complex who have subependymal giant cell astrocytoma, and in combination with Aromasin (exemestane) in hormone receptor-positive, HER2-negative breast cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||no benefit||Dactolisib + Everolimus||Phase Ib/II||Actionable||In a Phase Ib trial, the combination of BEZ235 and Afinitor (everolimus) resulted in limited efficacy in patients with advanced solid tumors and was discontinued due to multiple intolerable side effects (PMID: 28357727).||28357727|
|Unknown unknown||astrocytoma||not applicable||Dactolisib + Everolimus||Phase Ib/II||Actionable||In a Phase Ib trial, the combination of BEZ235 and Afinitor (everolimus) resulted in stable disease in a patient with astrocytoma (PMID: 28357727).||28357727|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01508104||Phase Ib/II||Dactolisib + Everolimus Everolimus||Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors||Terminated|